In the validation cohort, CLDN18 expression was found to be significantly (p < 0.05) associated with hypertriglyceridemia and hypercholesterolemia, but this effect was restricted to patients with obstructive CAD. Here, CLDN18 is linked to hypertriglyceridemia.